Facilitating Patient-Centered Decision Making Around the Timing of Direct-Acting Antivirals in Patients With Hepatitis C Virus and CKD

Overview

Journal Kidney Med

Specialty Nephrology

Date 2020 Aug 1

PMID 32734965

Authors

Meaghan Roche

Deirdre L Sawinski

Jordana B Cohen

Affiliations

Soon will be listed here.

References

Roth D, Nelson D, Bruchfeld A, Liapakis A, Silva M, Monsour Jr H . Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015; 386(10003):1537-45. DOI: 10.1016/S0140-6736(15)00349-9. View

Durand C, Bowring M, Brown D, Chattergoon M, Massaccesi G, Bair N . Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Ann Intern Med. 2018; 168(8):533-540. PMC: 6108432. DOI: 10.7326/M17-2871. View

Sawinski D, Forde K, Eddinger K, Troxel A, Blumberg E, Tebas P . Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV/HCV-coinfected recipients. Kidney Int. 2015; 88(2):341-9. PMC: 5113138. DOI: 10.1038/ki.2015.74. View

Sise M . Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function. Kidney Int Rep. 2019; 4(2):191-193. PMC: 6365390. DOI: 10.1016/j.ekir.2018.11.018. View

Cohen J, Locke J, Shelton B, Reed R, Mustian M, MacLennan P . Disparity in access to kidney allograft offers among transplant candidates with human immunodeficiency virus. Clin Transplant. 2018; 33(2):e13466. PMC: 6386602. DOI: 10.1111/ctr.13466. View

Henson J, Sise M . The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial. 2018; 32(2):108-118. PMC: 6410728. DOI: 10.1111/sdi.12759. View

Bernstein D, Tran A, Martin P, Kowdley K, Bourliere M, Sulkowski M . Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. Kidney Int Rep. 2019; 4(2):245-256. PMC: 6365509. DOI: 10.1016/j.ekir.2018.10.005. View

Sise M, Backman E, Ortiz G, Hundemer G, Ufere N, Chute D . Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD. Clin J Am Soc Nephrol. 2017; 12(10):1615-1623. PMC: 5628711. DOI: 10.2215/CJN.02510317. View

Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A . Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017; 377(15):1448-1455. DOI: 10.1056/NEJMoa1704053. View

10.

Cohen-Bucay A, Francis J, Gordon C . Timing of hepatitis C virus infection treatment in kidney transplant candidates. Hemodial Int. 2018; 22 Suppl 1:S61-S70. DOI: 10.1111/hdi.12643. View

11.

Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M . Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents. Am J Transplant. 2015; 16(5):1588-95. DOI: 10.1111/ajt.13620. View

12.

Axelrod D, Schnitzler M, Alhamad T, Gordon F, Bloom R, Hess G . The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes. Am J Transplant. 2018; 18(10):2473-2482. PMC: 6409105. DOI: 10.1111/ajt.14895. View

13.

Chute D, Sise M . Effect of the Opioid Crisis on the Donor Pool for Kidney Transplantation: An Analysis of National Kidney Deceased Donor Trends from 2010-2016. Am J Nephrol. 2018; 47(2):84-93. DOI: 10.1159/000486516. View

14.

de Kanter C, Drenth J, Arends J, Reesink H, Van Der Valk M, de Knegt R . Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2014; 53(5):409-27. DOI: 10.1007/s40262-014-0142-5. View

15.

Cohen J, Eddinger K, Shelton B, Locke J, Forde K, Sawinski D . Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes. Clin Kidney J. 2017; 10(4):564-572. PMC: 5569958. DOI: 10.1093/ckj/sfx048. View

16.

George N, Liapakis A, Korenblat K, Li T, Roth D, Yee J . A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment. Kidney Med. 2020; 1(4):200-206. PMC: 7380397. DOI: 10.1016/j.xkme.2019.06.003. View

17.

Sawinski D, Forde K, Lo Re 3rd V, Goldberg D, Cohen J, Locke J . Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study. Am J Kidney Dis. 2019; 73(6):815-826. PMC: 6535135. DOI: 10.1053/j.ajkd.2018.11.009. View

18.

Sawinski D, Patel N, Appolo B, Bloom R . Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation. Transplantation. 2016; 101(5):968-973. DOI: 10.1097/TP.0000000000001410. View

19.

Shelton B, Sawinski D, Linas B, Reese P, Mustian M, Hungerpiller M . Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation. Am J Transplant. 2018; 18(10):2483-2495. PMC: 6206868. DOI: 10.1111/ajt.15040. View

20.

Reese P, Abt P, Blumberg E, Goldberg D . Transplanting Hepatitis C-Positive Kidneys. N Engl J Med. 2015; 373(4):303-5. DOI: 10.1056/NEJMp1505074. View